Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).
FOSTER CITY, Calif. , July 17, 2019 /PRNewswire/ -- Mirum Pharmaceuticals, Inc., a clinical-stage therapeutics company developing a novel approach for treating cholestatic liver diseases, today announced the pricing of its initial public offering of 5,000,000 shares of its common stock at a price
First patient dosed in Phase 3 trial evaluating efficacy and safety of maralixibat Topline results expected in fourth quarter of 2020 FOSTER CITY, Calif. , July 9, 2019 /PRNewswire/ -- Mirum Pharmaceuticals today announced the dosing of the first patient in the Phase 3 MARCH-PFIC clinical trial of
Late breaker presentation of long-term analysis of Phase 2 INDIGO study shows sustained response and clinically-relevant growth accelerations in PFIC2 responders Data from Phase 2b ICONIC study show profound and durable improvements in itch severity and serum bile acids in children with Alagille
Maralixibat shows reductions in pruritus and serum bile acids in 48 week analysis of ICONIC Phase 2b study in Alagille syndrome patients Long-term analysis of INDIGO study of maralixibat shows sustained response and growth improvements in progressive familial intrahepatic cholestasis type two